Drug intelligence / Profile preview

HY-07121

Development stage
Phase 2
Lead developer
Sichuan Huiyu Pharmaceuticals
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

HY-07121 is a novel bispecific antibody fusion protein designed for cancer immunotherapy. It targets multiple immune checkpoints and cytokine pathways by combining anti-PD-1 and anti-TIGIT activities with IL-15/IL-15Rα agonism. The drug is intended to enhance the efficacy of tumor immunotherapy by both supplementing immune cell sources (increasing effector cells) and restoring the function of exhausted immune cells, thereby overcoming acquired resistance to immunotherapies. Developed as an injectable biologic, it is currently being evaluated in phase 1/2 clinical trials for advanced solid tumors[1][3][5][7].

02

Targets

IL15RA (Interleukin-15 receptor subunit alpha)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on HY-07121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-07121.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call